Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Receivables: 2014-2021

Historic Receivables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 7 years, with Sep 2021 value amounting to $1.5 million.

  • Viridian Therapeutics, Inc.\DE's Receivables rose 2494.74% to $1.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $1.8 million, marking a year-over-year increase of 38.82%. This contributed to the annual value of $24,000 for FY2018, which is 99.06% down from last year.
  • As of Q3 2021, Viridian Therapeutics, Inc.\DE's Receivables stood at $1.5 million, which was up 2,494.74% from $57,000 recorded in Q3 2020.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Receivables registered a high of $5.8 million during Q1 2018, and its lowest value of $4,000 during Q1 2020.
  • Moreover, its 3-year median value for Receivables was $248,000 (2020), whereas its average is $442,571.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Receivables plummeted by 99.90% in 2019 and then skyrocketed by 2,494.74% in 2021.
  • Viridian Therapeutics, Inc.\DE's Receivables (Quarterly) stood at $2.6 million in 2017, then tumbled by 99.06% to $24,000 in 2018, then fell by 29.16% to $979,000 in 2019, then crashed by 94.18% to $57,000 in 2020, then skyrocketed by 2,494.74% to $1.5 million in 2021.
  • Its Receivables was $1.5 million in Q3 2021, compared to $57,000 in Q3 2020 and $248,000 in Q2 2020.